Diaceutics is turning the precision-medicine “diagnostic gap” into a high-margin, recurring platform business—mapping, triggering, and activating biomarker patients in near real time for the world’s biggest pharma companies.
Overview
Diaceutics PLC operates as an enabling “infrastructure layer” for precision medicine commercialization, bridging the gap between biomarker-driven drug innovation and real-world patient access. The company targets a major inefficiency: despite heavy pharma investment in targeted therapies, roughly half of eligible patients can be “lost” because the right diagnostic tests aren’t ordered, results aren’t interpreted or routed correctly, or pathways are slowed by fragmented lab and clinical workflows. Diaceutics addresses this with the DXRX platform (“The Diagnostic Network®”), which integrates diagnostic testing data from a global network of 2,500+ laboratories and provides pharma brands with near real-time insights and activation tools to identify and treat eligible patients faster. The offering spans Insights (notably DXRX Signal triggers and mapping tools), Engagement (omnichannel education for physicians and labs within ~24 hours of a positive result), and the newer PMx end-to-end commercialization partnership model. The business is structurally shifting toward higher-margin recurring revenues; ~61% of revenue is now recurring via ARR subscriptions and multi-year data contracts, supported by strong expansion (NRR ~118%) and a sharply higher order book. With 18 of the top 20 global pharma companies as customers and growing enterprise-wide deployments, Diaceutics appears to be exiting an investment phase and entering a period of operating leverage and profitability expansion, while still trading at a valuation discount to UK life science peers.